Physician profile
Wayne C Wu
NPI 1962554436
$16,022.41
in general payments reported to CMS, 2019-2025
63 companies · $2,366 in 2025
The $2,366 reported for 2025 was more than what 95% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,178 · 2020: $2,380 · 2021: $1,782 · 2022: $2,622 · 2023: $2,141 · 2024: $2,552 · 2025: $2,366.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,248 · Gift: $805 · Education: $6.71.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,247.92 |
| Gift | $805.00 |
| Education | $6.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,697.99 | 2019-2025 | Vraylar, Ubrelvy, Qulipta |
| Novo Nordisk INC | $1,963.01 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals Lp | $1,567.24 | 2019-2025 | Breztri, Airsupra, Bevespi Aerosphere |
| Lilly USA, LLC | $1,434.83 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Pfizer INC. | $1,434.21 | 2019-2025 | |
| Sekisui Diagnostics LLC | $1,245.00 | 2022-2025 | |
| Medicure Pharma INC. | $600.00 | 2020 | |
| Astellas Pharma US INC | $397.06 | 2019-2025 | Veozah, Myrbetriq |
| Lundbeck LLC | $366.68 | 2022-2025 | Rexulti |
| Amgen INC. | $357.38 | 2019-2025 | Repatha, Otezla, Otezla |
| Janssen Pharmaceuticals, INC | $349.39 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $341.66 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $274.96 | 2019-2024 | Jardiance |
| Gilead Sciences, INC. | $253.35 | 2019-2025 | |
| Glaxosmithkline, LLC. | $203.27 | 2019-2025 | Shingrix, Arexvy, Trelegy Ellipta |
Show all 63 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Wayne Wu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.